These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 24816068)

  • 41. The value of antibodies 44-3A6, SM3, HBME-1, and thrombomodulin in differentiating epithelial pleural mesothelioma from lung adenocarcinoma: a comparative study with other commonly used antibodies.
    Ordóñez NG
    Am J Surg Pathol; 1997 Dec; 21(12):1399-408. PubMed ID: 9414183
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Diagnostic performance of immunohistochemistry markers for malignant pleural mesothelioma diagnosis and subtypes. A systematic review and meta-analysis.
    Parra-Medina R; Castañeda-González JP; Chaves-Cabezas V; Alzate JP; Chaves JJ
    Pathol Res Pract; 2024 May; 257():155276. PubMed ID: 38603842
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleura from lung adenocarcinoma.
    Ordóñez NG
    Am J Surg Pathol; 1998 Oct; 22(10):1215-21. PubMed ID: 9777983
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calretinin, thrombomodulin, CEA, and CD15: a useful combination of immunohistochemical markers for differentiating pleural epithelial mesothelioma from peripheral pulmonary adenocarcinoma.
    Comin CE; Novelli L; Boddi V; Paglierani M; Dini S
    Hum Pathol; 2001 May; 32(5):529-36. PubMed ID: 11381372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. h-Caldesmon, a useful positive marker in the diagnosis of pleural malignant mesothelioma, epithelioid type.
    Comin CE; Dini S; Novelli L; Santi R; Asirelli G; Messerini L
    Am J Surg Pathol; 2006 Apr; 30(4):463-9. PubMed ID: 16625092
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The "Brescia panel" (Claudin-4 and BRCA-associated protein 1) in the differential diagnosis of mesotheliomas with epithelioid features versus metastatic carcinomas.
    Bernardi L; Bizzarro T; Pironi F; Szymczuk S; Buda R; Fabbri E; Di Claudio G; Rossi G
    Cancer Cytopathol; 2021 Apr; 129(4):275-282. PubMed ID: 33045147
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peritoneal malignant mesothelioma (PMM), and primary peritoneal serous carcinoma (PPSC) and reactive mesothelial hyperplasia (RMH) of the peritoneum. Immunohistochemical and fluorescence in situ hybridisation (FISH) analyses.
    Kawai T; Tominaga S; Hiroi S; Ogata S; Nakanishi K; Kawahara K; Sonobe H; Hiroshima K
    J Clin Pathol; 2016 Aug; 69(8):706-12. PubMed ID: 26729015
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Uroplakin-IIIb as a novel immunohistochemical marker for mesothelioma.
    van Pel DM; Cheung S; Ionescu DN; Churg A
    Hum Pathol; 2023 Nov; 141():64-68. PubMed ID: 37776956
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Mucin 21 is a novel, negative immunohistochemical marker for epithelioid mesothelioma for its differentiation from lung adenocarcinoma.
    Kai Y; Amatya VJ; Kushitani K; Kambara T; Suzuki R; Tsutani Y; Miyata Y; Okada M; Takeshima Y
    Histopathology; 2019 Mar; 74(4):545-554. PubMed ID: 30329165
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Value of calretinin immunostaining in differentiating epithelial mesothelioma from lung adenocarcinoma.
    Ordóñez NG
    Mod Pathol; 1998 Oct; 11(10):929-33. PubMed ID: 9796717
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Claudin 3, 4, and 15 expression in solid tumors of lung adenocarcinoma versus malignant pleural mesothelioma.
    Chaouche-Mazouni S; Scherpereel A; Zaamoum R; Mihalache A; Amir ZC; Lebaïli N; Delaire B; Gosset P
    Ann Diagn Pathol; 2015 Aug; 19(4):193-7. PubMed ID: 25935651
    [TBL] [Abstract][Full Text] [Related]  

  • 52. GATA3 Immunohistochemistry for Distinguishing Sarcomatoid and Desmoplastic Mesothelioma From Sarcomatoid Carcinoma of the Lung.
    Berg KB; Churg A
    Am J Surg Pathol; 2017 Sep; 41(9):1221-1225. PubMed ID: 28614203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Analysis of expression patterns of breast cancer-specific markers (mammaglobin and gross cystic disease fluid protein 15) in lung and pleural tumors.
    Takeda Y; Tsuta K; Shibuki Y; Hoshino T; Tochigi N; Maeshima AM; Asamura H; Sasajima Y; Ito T; Matsuno Y
    Arch Pathol Lab Med; 2008 Feb; 132(2):239-43. PubMed ID: 18251583
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Diagnostic utility of D2-40 and podoplanin in effusion cell blocks.
    Bhalla R; Siddiqui MT; Mandich D; Cartun RW; Fiel-Gan MD; Nassar A; Mandavilli SR
    Diagn Cytopathol; 2007 Jun; 35(6):342-7. PubMed ID: 17497664
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Melan A (A103) is not a marker of mesothelioma.
    Ordóñez NG; Shen SS; Zenali M; Deavers MT
    Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):181-4. PubMed ID: 22820661
    [TBL] [Abstract][Full Text] [Related]  

  • 56. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma.
    Ordóñez NG
    Hum Pathol; 2005 Apr; 36(4):372-80. PubMed ID: 15891998
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Utility of a CEA, CD15, calretinin, and CK5/6 panel for distinguishing between mesotheliomas and pulmonary adenocarcinomas in clinical practice.
    Mohammad T; Garratt J; Torlakovic E; Gilks B; Churg A
    Am J Surg Pathol; 2012 Oct; 36(10):1503-8. PubMed ID: 22982894
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Expression of mesothelin as a potential diagnostic marker in mesothelioma].
    Kuribayashi K; Fukuoka K; Nakajima T; Miyake M; Miyata S; Tamura K; Iida S; Yamada S; Murakami A; Hirano H; Nakano T
    Nihon Kokyuki Gakkai Zasshi; 2008 Jan; 46(1):3-9. PubMed ID: 18260303
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The value of 'mesothelium-associated' antibodies in distinguishing between metastatic renal cell carcinomas and mesotheliomas.
    Osborn M; Pelling N; Walker MM; Fisher C; Nicholson AG
    Histopathology; 2002 Oct; 41(4):301-7. PubMed ID: 12383211
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Utility of Methylthioadenosine Phosphorylase Compared With BAP1 Immunohistochemistry, and CDKN2A and NF2 Fluorescence In Situ Hybridization in Separating Reactive Mesothelial Proliferations From Epithelioid Malignant Mesotheliomas.
    Berg KB; Dacic S; Miller C; Cheung S; Churg A
    Arch Pathol Lab Med; 2018 Dec; 142(12):1549-1553. PubMed ID: 30059257
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.